Compounds > perifosine
Page last updated: 2024-09-04

perifosine and carfilzomib

perifosine has been researched along with carfilzomib in 5 studies

Compound Research Comparison

Studies
(perifosine)		Trials
(perifosine)		Recent Studies (post-2010)
(perifosine)		Studies
(carfilzomib)		Trials
(carfilzomib)		Recent Studies (post-2010) (carfilzomib)
24531140748121716

Protein Interaction Comparison

ProteinTaxonomyperifosine (IC50)carfilzomib (IC50)
Proteasome subunit beta type-11Homo sapiens (human)0.0608
26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)0.0086
26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)0.0086
26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)0.0086
Proteasome subunit alpha type-7Homo sapiens (human)0.0608
26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)0.0086
26S proteasome regulatory subunit 6AHomo sapiens (human)0.0086
Proteasome subunit beta type-1Homo sapiens (human)0.5937
Proteasome subunit alpha type-1Homo sapiens (human)0.0608
Proteasome subunit alpha type-2Homo sapiens (human)0.0608
Proteasome subunit alpha type-3Homo sapiens (human)0.0608
Proteasome subunit alpha type-4Homo sapiens (human)0.0608
Proteasome subunit beta type-8Homo sapiens (human)0.0407
Proteasome subunit beta type-9Homo sapiens (human)0.7166
Proteasome subunit alpha type-5Homo sapiens (human)0.0608
Proteasome subunit beta type-4Homo sapiens (human)0.0608
Proteasome subunit beta type-6Homo sapiens (human)0.199
Proteasome subunit beta type-5Homo sapiens (human)0.0237
26S proteasome regulatory subunit 7Homo sapiens (human)0.0086
Proteasome subunit beta type-10Homo sapiens (human)0.1339
26S proteasome regulatory subunit 6BHomo sapiens (human)0.0086
26S proteasome non-ATPase regulatory subunit 8Homo sapiens (human)0.0086
Proteasome subunit beta type-3Homo sapiens (human)0.0608
Proteasome subunit beta type-2Homo sapiens (human)0.7493
26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)0.0086
26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)0.0086
26S proteasome complex subunit SEM1Homo sapiens (human)0.0086
Proteasome subunit alpha type-6Homo sapiens (human)0.0608
26S proteasome regulatory subunit 4Homo sapiens (human)0.0086
26S proteasome regulatory subunit 8Homo sapiens (human)0.0086
26S proteasome regulatory subunit 10BHomo sapiens (human)0.0086
Glutathione S-transferase omega-1Homo sapiens (human)0.15
26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)0.0086
26S proteasome non-ATPase regulatory subunit 6Homo sapiens (human)0.0086
Proteasomal ubiquitin receptor ADRM1Homo sapiens (human)0.0086
Proteasome subunit alpha-type 8Homo sapiens (human)0.0608
Proteasome subunit beta type-7Homo sapiens (human)0.0578
26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)0.0086
26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)0.0086

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
El-Amm, J; Tabbara, IA1
Orlowski, RZ1
Cavallo, F; Genadieva-Stavric, S; Palumbo, A1
Iida, S; Ri, M1

Reviews

4 review(s) available for perifosine and carfilzomib

ArticleYear
Emerging therapies in multiple myeloma.
    American journal of clinical oncology, 2015, Volume: 38, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Signal Transduction; Thalidomide

2015
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
    Seminars in oncology, 2013, Volume: 40, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Phosphorylcholine; Piperidines; Proteasome Inhibitors; Pyridines; Remission Induction; Thalidomide; Thiazoles; Treatment Outcome; Vorinostat

2013
New approaches to management of multiple myeloma.
    Current treatment options in oncology, 2014, Volume: 15, Issue:2

    Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Depsipeptides; Frail Elderly; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Pyrazines; Quality of Life; Recurrence; Thalidomide; Treatment Outcome

2014
[Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:3

    Topics: Activating Transcription Factor 3; Activating Transcription Factor 4; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase 5; Cytokines; Dexamethasone; DNA-Binding Proteins; Drug Discovery; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Indoles; Kruppel-Like Transcription Factors; Molecular Targeted Therapy; Multiple Myeloma; Nicotinamide Phosphoribosyltransferase; Oligopeptides; Panobinostat; Phosphorylcholine; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Regulatory Factor X Transcription Factors; Toyocamycin; Transcription Factors

2014

Other Studies

1 other study(ies) available for perifosine and carfilzomib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013